Many clinicians perceive guidelines as tedious and unnecessarily complex, but consider them a necessary 'evil' for clinical practice. Others follow guidelines rigorously often at the expense of recognising that guidelines are for populations and not individuals and medicine is not an exact science consisting of binary decision but rather an art, which becomes increasingly relevant at the edges of evidence where the art is in applying what (little) scientific evidence exists. In this regard, on the back of a plethora of robust cardiovascular (CV) outcomes trials, global guidelines for cardiovascular disease (CVD) have been quick to construct the evidence base for CVD prevention, and in particular with respect to recommendations for lipid lowering therapy with statins where benefit far outweighs harm. Although the approach in different guidelines may vary, the debate on both sides of the Atlantic has witnessed a convergence where recommendations for the secondary prevention of CVD are concerned. 1, 2 The same is true for the treatment of primary hypercholesterolaemia including familial hypercholesterolemia and diabetes mellitus (DM); in the latter two, recommendations are similar but differ in their interpretation of the strength of evidence but are otherwise concordant. In contrast, the situation is different for the primary prevention of CVD i.e. amongst those individuals free from CVD for whom decisions are made on the future probablity of developing CVD. In this regard there are two areas in which the American College of Cardiology/ American Heart Association (ACC/AHA) 2013 guidelines and the European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) 2011 guidelines diverge materially. 1, 2 First, the ACC/AHA guidelines have lowered the threshold for the prevention of vascular disease from a 10 year risk of 20% to one of 7.5% which will result in considerably more patients being offered statins. These will include more older individuals who largely by virtue of age will be over this risk threshold but, fortunately, also younger individuals who would otherwise wait many more years before being offered therapy will now be eligible under the revised guidance. If earlier therapy is the key to lifelong prevention then reducing the treatment threshold is particularly advantageous for a younger person that has many more disease free life years to gain.
Second, the ACC/AHA 2013 guidelines moved away from the Framingham risk equation to a pooled mixed cohorts risk equation. In contrast, if the ESC/EAS 2016 Prevention guidelines are a guide to the anticipated ESC/EAS 2016 Lipid guidelines, 3 then these will continue to recommend SCORE and are unlikely to change their threshold for offering treatment. Last, and perhaps most importantly, in addition to constructing recommendations based on data from multiple large randomized controlled outcomes trials, primary prevention guidelines base recommendations on the performance of equations predicting different CV endpoints derived from large epidemiological cohorts. Evaluating the performance of risk equations is complex and no single metric can provide a complete picture. Three measures of performance are generally used to provide a comprehensive picture: discrimination (correct identification of cases and noncases), calibration (predicted and observed event rates similar across the risk distribution) and reclassification (are cases and non-cases better classified for decision-making?). In a previous commentary in this Journal in 2014 on the ACC/AHA guidelines, we critically wrote that the mixed pool risk calculator used to assess CVD risk for primary prevention had not been fully evaluated. 4 Our remarks are no longer valid with the appearance of the current analysis from a Danish cohort. 5 In the present issue of the European Heart Journal, Mortensen and colleagues evaluated the performance of the US pooled cohorts equation (US-PCE) and compared this to the SCORE risk algorithm derived in Europe. In a large contemporary study from Copenhagen which enrolled 44 889 participants between 2003 to 2009 and reports on 2217 events, the authors report that the US-PCE outperformed SCORE with respect to every metric used to assess the performance of any given model. For instance, they report that predicted-to-observed event ratio was 1.2 using US-PCE for any atherosclerotic cardiovascular disease (ASCVD) vs. 5 for SCORE for fatal ASCVD. Also, using ACC/AHA vs. ESC/EAS-defined statin eligibility criteria led to a 62% gain in sensitivity as well as to a much smaller 35% loss of specificity.
Part of the explanation for these discrepancies is intuitive, but the other part is not and requires critical consideration. For instance, in US populations, the US-PCE equations, derived from six cohorts of Caucasian and African American men and women, perform better than the earlier Framingham equations which predicted coronary endpoints such as myocardial infarction and coronary death because these new equations also incorporate stroke risk. 6 Not unanticipated, the US-PCE performs less well in low risk US populations, such as highly educated health professionals and high socioeconomic, insured populations. 7, 8 So it is somewhat surprising that the US-PCE were well-calibrated around statin decision cut-points in an urban, northern European population. Therefore the question is; do these data from Denmark provide compelling evidence to abandon SCORE across Europe and move to the US-PCE in one swoop? The answer is most likely no; there are several limitations in the performed analyses and some of the data is presented in a confusing manner. Nevertheless, there are some key points in this article which urge us to consider modifications to SCORE across Europe. First, SCORE is derived from cohorts who were part of the original MONICA studies and perhaps no longer reflect a contemporary population. In particular, cohorts need to reflect the changing epidemiology of CVD over the past few decades that have occurred in particular within high income countries with dramatic declines in mortality from CVD but without a similar decline in incident nonfatal CV events. 9, 10 As such this may be part of the reason that a prediction tool derived from contemporary cohorts US-PCE performed better when applied to another contemporary population. In contrast, in our own analysis from the much older cohort of EPIC NORFOLK, the SCORE and US-PCE performed equally well but that population may have been more similar to some of the historical cohorts from which SCORE is derived. Second, the contribution of non-fatal events is critical. The US-PCE includes non-fatal events, which helps to improve the power and precision of this equation. There were 10 times more non-fatal (approximately 2000 events) than fatal ASCVD events (approximately 200), and so less surprising that the European derived SCORE cutpoints based on CV mortality performed poorly. Indeed, in men between 40 and 60 years fatal CVD rates increased from 0.2/1000/ year to 0.6/1000/year, and in contrast, the corresponding figures were 2 and 8.7/1000/year for any ASCVD event. In women within a similar age range, this was even more marked with rates of 0/1000/ year increasing to 0.4/1000/year for fatal events and ranging from 1.8 to 6.2/1000/year for any ASCVD event (see Supplementary material online, Figure S2 ). Risk prediction tools globally tend to overestimate risk in older/higher risk individuals and underestimate risk in younger individuals, women and lower risk groups. This is again reflected in the analysis from Denmark, although the difference between predicted and observed is much more marked in higher risk categories using fatal events only (SCORE) rather than fatal and non-fatal events combined US-PCE. For instance, in sensitivity analyses restricted to the 40-65 age range where SCORE is designed to perform, there were only 54 and 24 fatal events in men and women, respectively vs. 733 and 579 fatal and non-fatal events combined. Whether the superiority of US-PCE over SCORE is simply a function of the relationship between exposures to different endpoints or simply an issue of power or both cannot be resolved by this analysis.
Third, the authors demonstrate that using the PCE decision cutpoints the ACC/AHA 2013 guidelines increase the eligibility for statin therapy. It is intuitive that if you have a lower threshold for initiation of statin therapy then more patients would be offered this medication, so this is not surprising. What is interesting is that Net Reclassification Index (NRI) which assesses the overall ability to correctly classify individuals into groups who develop events and would be offered therapy as well as reclassifying individuals to treatment groups who would not be offered therapy and remain event free improved by 27% for any ASCVD event and 40% for fatal events when comparing the decision cutpoints for ESC/EAS guidelines vs. SCORE. The performance of NRI is a function of the chosen decision cutpoint and as such the data by Mortensen et al would suggest that a SCORE risk of 2.4% equates to a US-PCE of 7.5% which is also supported by our prior observations in EPIC Norfolk. 4 Further examination of the demographic characteristics of people considered eligible for statins based on ESC/EAS 2013 decision cutpoints vs. ACC/AHA guidance suggests that among men low-density lipoprotein (LDL)-C levels are 0.9 mmo/L higher, blood pressure (BP) 12 mmHg higher and there is a 15% greater prevalence of smokers. The corresponding figures in women are 1.4 mmol/L higher LDL-C, 2 mmHg higher BP and 7% more smokers. Thus the ESC/EAS guidelines are offering statins to people who are at much higher risk factor burden than the American counterpart. Given the wealth of data, including the recent HOPE three trial 11 where those with event rates as low as 0.7% per year for fatal and non-fatal events derived benefit from statins, the time has surely now come in Europe to lower the threshold for statin initiation. In this regard, the performance of SCORE or other risk tools should be re-evaluated, on a country by country basis, and need to include fatal and non-fatal events in a contemporary population. Also, such an endeavour needs to include risk factors which reflect the current determinants of CVD calibrated for the population they are meant to apply to. Final, a note of caution is needed against over-interpretation of the data of Mortensen et al., which should instead be the starting point for a wider discussion. This results from the fact that the authors confuse issues considerably by mixing up the performance of the risk equations in primary prevention populations to guidelines which recommend class I or class II indication based on RCTs. In some populations risk prediction tools should not be applied to determine the indication for lipid lowering. These include those with severely elevated LDL-C levels above 190 mg/dl (US and Europe), individuals with chronic kidney disease (Europe), and DM (US and Europe). Unfortunately, the analyses by Mortensen et al only excluded individuals with diabetes, so whilst it is likely that the US-PCE does overall perform better than SCORE, it is uncertain whether it performs quite as well as the headline grabbing results the authors report.
Last, it will be important, as highlighted recently, to assess the impact of statin therapy not only as a function of lifetime ASCVD risk but also based on absolute levels of LDL-C. As such, young individuals with elevated LDL-C might derive considerable benefit and potentially more than an older individual with a low LDL-C from LDL-C lowering therapies as the magnitude of risk reduction is proportional to the absolute reduction in LDL-C. 12 Compelling evidence from genetic studies also suggests that maintaining a lower LDL-C throughout life likely have a greater impact on CVD risk than later interventions when disease is more advanced or the burden of risk factors too great to obtain the same cumulative reductions in risk derived from modest reductions in LDL-C but for longer period of time. This is likely to be the next key challenge in truly delivering the promise of preventive CV medicine.
